Use of Somatropin in Turner Syndrome
The Use of Norditropin® in Turner's Syndrome
This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.
2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
Inclusion Criteria: Turner Syndrome Not previously treated with growth hormone or androgen Well-documented height over the previous 12 months Informed consent of parents (and child if appropriate) Exclusion Criteria: Growth hormone (GH) deficiency based on a GH stimulation test